月別アーカイブ: 2014年2月

Pharmacy education growing rapidly, easing workforce shortages

The landscape for pharmacy education has changed dramatically in recent years, as rapid growth in new schools and student enrollment has eased state and regional workforce shortages, according to a new report from the University of California.

“An Era of Growth and Change: A Closer Look at Pharmacy Education and Practice” follows a report UC issued last May examining growth and recent trends in health professions education.

Enrollment in pharmacy education programs has increased significantly, following a nationwide pharmacist shortage that developed in the late 1990s. National trends now suggest that the supply of pharmacists is growing much faster than previously projected. Since 2005, the number of accredited U.S. pharmacy schools has increased by 48 percent, from 87 to 129, with most of the growth occurring at private institutions.

“Enrollment in pharmacy education programs has grown substantially in the past decade — faster than the previous 25 to 30 years,” said Cathryn Nation, M.D., UC associate vice president for health sciences. “This report will be an important tool for policymakers and higher education leaders, highlighting trends that will inform efforts to address the challenges posed by health care reform, an aging population and the ongoing demand for pharmacy services.”

In particular, California has been home to significant growth in pharmacy education. Since 2002, four new pharmacy schools have opened in the state, doubling the number of programs in California from four to eight over the past decade. Other institutions appear interested in opening new pharmacy schools in California within the next few years.

Highlights of the report include:

  • Demand for pharmacists in California is beginning to fall in balance with the state’s growing supply of pharmacists.
  • Significant growth in pharmacy educational opportunities has occurred throughout California, with the majority of enrollment increases happening at private institutions.
  • California faces a shortage of well-qualified faculty to train future pharmacists.
  • Disparities in health status, changing demographics and the evolving roles of pharmacists in health care delivery will require increased diversity and cultural competence of the workforce.
  • There is a substantial mismatch between the number of residency training positions available and increasing student interest (pharmacy residency positions are post-graduate, advanced training positions that are available following completion of a Pharm.D. degree).

The report includes findings about California’s educational programs and recommendations relevant to the UC system, which operates two pharmacy schools: UC San Francisco, ranked as the nation’s top pharmacy school by U.S. News & World Report, and UC San Diego, whose pharmacy school opened in 2002.

“As we look to the future, pharmacy education must remain relevant and aligned with the needs of patients,” said B. Joseph Guglielmo, Pharm.D., dean of the UCSF School of Pharmacy. “This report provides an overview of the pharmacy landscape and a valuable resource for the UC system and our colleagues throughout the state.”

The UC system operates the nation’s largest health sciences instructional program, with 17 professional schools in seven major health professions, including pharmacy education. UC’s two pharmacy schools accounted for 182 (approximately 21 percent) of California’s 849 graduating pharmacy students in 2011.

California pharmacy schools

Public schools/institutions
UC San Francisco
UC San Diego (first class admitted in 2002)

Private schools/institutions
University of the Pacific
University of Southern California
Western University of Health Sciences
Loma Linda University (first class admitted in 2002)
Touro University (first class admitted in 2005)
California Northstate University (first class admitted in 2008)

University of California Health includes five academic health centers with 10 hospitals and 17 health professional schools in seven fields on seven UC campuses — UC Berkeley, UC Davis, UC Irvine, UCLA, UC Riverside, UC San Diego and UC San Francisco.

Additional contacts
UC San Francisco
Kristen Bole
(415) 502-6397 (NEWS)
kristen.bole@ucsf.edu

UC San Diego
Jacqueline Carr
(619) 543-6427
jcarr@ucsd.edu

Source Article from http://www.universityofcalifornia.edu/press-room/pharmacy-education-growing-rapidly-easing-workforce-shortages
Pharmacy education growing rapidly, easing workforce shortages
http://www.universityofcalifornia.edu/press-room/pharmacy-education-growing-rapidly-easing-workforce-shortages
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo News Search Results
pharmacy – Yahoo News Search Results





Pharmacy Benefit Management in the US – Industry Market Research Report

LONDON, Feb. 27, 2014 /PRNewswire/ — Reportbuyer.com just published a new market research report:

Pharmacy Benefit Management in the US – Industry Market Research Report

Pharmacy Benefit Management

Though it felt the recession’s effects, the Pharmacy Benefit Management industry has recovered quickly and is poised to grow on the back of rising insurance coverage and increased physician visits, which will yield a higher number of prescriptions filled. As the median age of the US population continues to rise, more Americans will rely on medications, increasing demand for the industry’s services from insurers and employer-sponsored coverage plans. As more patients choose generics over more expensive brand names, however, industry profit margins are expected to make little progress in the coming years.
This industry includes firms that provide pharmacy benefit management services. Industry firms are third-party administrators of government and employer-sponsored prescription drug programs. They are primarily responsible for processing and paying prescription drug claims.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.

TABLE OF CONTENTS

ABOUT THIS INDUSTRY
Industry Definition
Main Activities
Similar Industries
Additional Resources

INDUSTRY AT A GLANCE

INDUSTRY PERFORMANCE
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle

PRODUCTS & MARKETS
Supply Chain
Products & Services
Demand Determinants
Major Markets
International Trade
Business Locations

COMPETITIVE LANDSCAPE
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Basis of Competition
Barriers to Entry
Industry Globalization

MAJOR COMPANIES

OPERATING CONDITIONS
Capital Intensity
Technology & Systems
Revenue Volatility
Regulation & Policy
Industry Assistance

KEY STATISTICS
Industry Data
Annual Change
Key Ratios

JARGON & GLOSSARY

MAJOR COMPANIES

CVS Caremark
UnitedHealth Group Inc.
Express Scripts Holding Company

Read the full report:
Pharmacy Benefit Management in the US – Industry Market Research Report
http://www.reportbuyer.com/countries/north_america/usa/pharmacy_benefit_management_us_industry_market_research_report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Marketing

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

Source Article from http://ca.finance.yahoo.com/news/pharmacy-benefit-management-us-industry-172600645.html
Pharmacy Benefit Management in the US – Industry Market Research Report
http://ca.finance.yahoo.com/news/pharmacy-benefit-management-us-industry-172600645.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo News Search Results
pharmacy – Yahoo News Search Results





BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results

PARIS–(BUSINESS WIRE)–

Regulatory News :

BioAlliance Pharma SA (BIO.PA) (Euronext Paris – BIO), an innovative
Company dedicated to the development of orphan oncology products, today
published its 2013 financial results, major achievements on its clinical
programs in 2013 and its prospects 2014.

The year 2013 was marked by key milestones achieved in the development
of its two major products, Livatag® and Validive®:

  • ReLive, Livatag® phase III clinical trial in the treatment of primary
    liver cancer, has continued in line with the international expansion
    strategy of the study.
    Since mid-2013 the trial has been extended
    to 7 European countries and is being implemented in the United States,
    following the Investigational New Drug (IND) authorization received
    from the FDA at the end of 2013. More than 100 patients have been
    enrolled and the geographic expansion will support patients’ enrolment
    increase. Last patient is scheduled to be enrolled late 2015 with
    preliminary results expected in 2016.
    Finally, as part of its
    bi-annual review, the international Board of independent experts (Data
    Safety Monitoring Board) confirmed the product’s good safety profile
    twice in 2013.
  • Validive® phase II clinical trial in the prevention of severe oral
    mucositis has been strongly accelerated and nearly 95% of the patients
    have already been enrolled to date. The Company expects to complete
    patient recruitment in the coming weeks with preliminary results
    expected in the second half of 2014.
    Fast track
    designation has been granted from US FDA to Validive®, a status
    dedicated to treatments addressing very serious diseases, with high
    unmet medical needs. This designation will allow for the accelerated
    review of clinical data, thereby reducing the time to potential market
    authorization by about 3 to 6 months.

Both products, at an advanced stage of their development, target severe
diseases with poor therapeutic alternatives. Positioned in markets of
hundreds of millions Euros, they represent major growth drivers for the
Company in the short and medium term.

For the second time, BioAlliance Pharma has succeeded to register a drug
in the US with NDA granted for Sitavig® in the treatment of recurrent
labial herpes. Advanced discussions regarding partnerships are ongoing
and agreements are expected in the coming months.

Key figures from the consolidated financial statements for the financial
year 2013 are summarized in the table below:

Consolidated income amounted to €1.5 million in 2013 and mainly resulted
from the commercial partners’ activity related to Loramyc®/Oravig®. The
difference as compared to the previous year is due to the recognition in
2012 of non-recurrent payments under license agreements with Therabel
and Vestiq companies for a total amount of €2.5 million. Considering
Oravig®’s sales level, no payment of milestone from American partner
Vestiq is expected in the short term.

Operating expenses amounted to €17 million (+ 8.6% as compared to 2012),
including €10 million expenses for R&D, increased by 26% compared to
2012, excluding regulatory taxes. This significant financial effort has
primarily supported the acceleration and international expansion of
Validive® and Livatag® clinical programs, while also reflecting the
Company’s efforts to control general and administrative expenses.

The consolidated cash position as of December 31, 2013 amounted to €11.3
million, notably following a €8.4 million fund raising realized in July
2013, which was oversubscribed by 155%. Beyond licensing agreements
expected in the coming months, the Company is considering the most
appropriate funding strategy to pursue the dynamic deployment of its
programs.

“The Company’s strategy is to become a key player in the orphan
oncology diseases and its growth will be sustained by both its key
products in these pathologies. In 2013, significant progress has been
achieved on these programs, and especially in the United States with the
IND for Livatag® and the Fast track designation for Validive®. Phase II
preliminary results for Validive®, expected in Q4 2014 will represent a
major catalyst of value creation for this asset. Based on our expertise
and supported by the dynamic advancement of our programs, BioAlliance
has everything in place for a strong growth”,
comments Judith
Greciet, CEO of BioAlliance Pharma.

BioAlliance will comment on major current issues and its annual
financial statements during its SFAF meeting which will be held on
February 28, 2014 at 9:30am at the Company’s headquarters (49 boulevard
Martial Valin, Paris 15°, France), and during the audio/web conference
the same day at 6:00 pm:

Tel: +33 (0)1 70 77 09 37
https://bioalliancepharma-en.webex.com/bioalliancepharma-en/j.php?MTID=mb91c47bc59bbfc7d5785a7fd1dd34d8c
/ Meeting nb: 702 301 629 / Password: product
For replay: Nb
+33 (0)1 72 00 15 00 / Conf Nb: 285911#

About BioAlliance Pharma
Dedicated to cancer treatments with
a focus on resistance targeting and orphan products, BioAlliance Pharma
conceives and develops innovative products for orphan or rare diseases.
Created
in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance
Pharma’s ambition is to become a leading player in these fields by
coupling innovation to patient needs. The company’s teams have the key
competencies required to identify, develop and register drugs in Europe
and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products
Livatag® (Doxorubicin
Transdrug™) (primary liver cancer): Phase III on going
Validive®
(Clonidine Lauriad®) (mucositis): Phase II on going
AMEP®
(invasive melanoma): Phase I on going
For more information, visit
the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date
and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise.

For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of BioAlliance
Pharma SA to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the 2012 Reference Document filed with the AMF on April 18,
2013, which is available on the AMF website (
http://www.amf-france.org)
or on BioAlliance Pharma SA’s website).

Source Article from http://finance.yahoo.com/news/bioalliance-pharma-provides-updates-major-170000618.html
BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results
http://finance.yahoo.com/news/bioalliance-pharma-provides-updates-major-170000618.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results